Brief: Aprea Therapeutics CEO Issues Letter To Shareholders Highlighting Outlook For 2026
18/12/2025 15:17
Dec 18 (Reuters) - Aprea Therapeutics Inc APRE.O: APREA THERAPEUTICS CEO ISSUES LETTER TO SHAREHOLDERS HIGHLIGHTING PIPELINE PROGRESS IN 2025 AND OUTLOOK FOR 2026 APREA THERAPEUTICS INC - PAUSES ENROLLMENT IN ABOYA-119 STUDY MONOTHERAPY ARMS Source text: ID:nGNX1SSvv2 Further company coverage: APRE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aprea Therapeutics
See all newsAprea Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Aprea Therapeutics Q2 net loss widens on higher R&D costs
Aprea Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Aprea Therapeutics Provides Acesot-1051 Program Update For Wee1 Inhibitor Apr-1051 Accelerating And Expanding Enrollment. Clinical Data Presentation Planned For Q4 2026
Brief: Aprea Therapeutics - Files For Resale Of Up To 5.5 Million Shares By Selling Stockholders - SEC Filing